• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Jawboning by HHS Doesn't Scare Insurers

Article

The Department of Health and Human Services isn’t that much of a bully, it turns out.

Health insurers flagged by the department for “unreasonable” premium hikes are refusing to back down in the first year of HHS’s new rate review authority.

Read the full story: http://hcp.lv/JwIJET

Source: Politico

The health reform law gave HHS the power to scrutinize “unreasonable” rate hikes in states that didn’t have robust review programs. But “scrutiny” doesn’t give the department power to actually block the rates from going into effect.

Related Videos
Hearn Jay Cho, MD, PhD
Nicoletta Colombo, MD, PhD
Adam Brufsky, MD, PhD
Screenshot of an interview with Stephen Nicholls, MBBS, PhD
Screenshot of an interview with Martha Gulati, MD
Screenshot of an interview with Vallerie McLaughlin, MD
Nicoletta Colombo, MD, PhD
Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Related Content
The study provides a timely real-world example of how technology-enabled hypertension management can fit into the broader financial architecture of chronic disease care. | Image credit: Dzianis Vasilyeu - stock.adobe.com

Remote Patient Monitoring Shows Potential for Managing Complex Chronic Disease

December 27th 2025
Article

A reimbursable, team-based remote blood pressure monitoring program significantly improved hypertension control in patients with multiple chronic conditions.

Read More

Managed Care Cast Square thumbnail

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025
Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

FDA approval with stamp. | Image Credit: Surendra – stock.adobe.com

FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy

December 22nd 2025
Article

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

Read More

Managed Care Cast Square thumbnail

Managed Care Cast Presents: Leveraging Topical Therapies for Pediatric Atopic Dermatitis

October 30th 2025
Podcast

Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.

Listen

Pharma Innovation | Image: Pexels

Pharma Leaders Stress Policy, Value-Based Care, and Collaboration as Key to Improving Drug Access

December 19th 2025
Article

Industry leaders discuss how policy, pricing, and innovation will shape the future of oncology care and patient access.

Read More

Lavi Kwiatkowsky | Image: LinkedIn

Canopy’s Remote Therapeutic Monitoring Cuts Infection-Related Hospitalizations by Half in Patients With Blood Cancers

December 19th 2025
Article

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.